Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
placebo in reducing body weight after 24 weeks of treatment, with a minimum of 12 weeks at top dose
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly, targeting GIP, GLP-1, and glucagon receptors, showing significant promise in clinical trials for obesity and type 2 diabetes due to its potent effects on appetite, energy expenditure, and glycemic control
Did You Know: Studies examining body composition during GLP-1 therapy found the best outcomes in patients exercising four to seven days weekly with resistance training three to five of those days
Chronic weight management: GLP-1s have gained recent popularity for their use in chronic weight management
3 Degradation of GLP-1 and production of GLP-1RAs GLP-1 (7-36)NH 2 acts as the active form, and the N-terminal end of this peptide is readily recognized by dipeptidyl peptidase-4 (DPP-4), an exopeptidase released from vascular endothelium and other tissues that can be quickly cut between the 2nd and 3rd amino acids to produce GLP-1 (9-36)NH 2
1 The reduced incretin response leads to decreased insulin release and increased blood glucose concentrations following a meal
US$ 26.53
US$ 20.58
US$ 29.58
US$ 21.76
